[1]Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density[J]. Cell,1997,89(7):309-319.
[2]廖二元,谭利华.代谢性骨病学[M].北京:人民卫生出版社,2002:209-241.
[3]Sato K, Niessner A, Kopecky SL, et al. TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque[J]. J Exp Med 2006,203(3):239-250.
[4]Bennett BJ,Scatena M,Elizabeth A,et a1.Osteorotegerin inactivation accelerates advanced athersclerotic lesion progression and calcification in older apoE-/-Mice[J].Arterioscler Thromb Vasc Biol,2006,26(9):2114-2117.
[5]Ovchinnikova O, Gylfe A, Bailey L,et a1.Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice-brief report[J]. Arterioscler Thromb Vasc Biol,2009,29(10):1478-80.
[6]Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease[J]. Circulation,2002,106(11):1192-1194.
[7]Helske S, Kovanen PT, Lindstedt KA, et al. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload[J].Eur J Heart Fail,2007,9(5):357-363.
[8]Ohmori R, Momiyama Y, Taniguchi H, et al. Association between osteoprotegerin gene polymorphism and coronary artery disease in Japanese men[J]. Atherosclerosis,2006,187(2):215-217.
[9]Crisafulli A,Micari A,Altavilla D,et al.Serum levels of osteoprotegerin and RANKL in patients with ST-elevation acute myocardial infarction[J].Clin Sci(Lond),2005,109(4):389-395.
[10]Omland T,Drazener MH,Ueland T,et al.Plasma osteoprotegenrin levels in the general populationg:relation to indices of left ventricular structure and function[J].Hypertension,2007,49(6):1392-1398.
[11]Omland T, Ueland T, Jansson AM, et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes[J]. J Am Coll Cardiol,2008,51(6):627-633.
[12]Stefan K,George S,George W,el al.Osteorotegerin is a risk factor for progressive atherosclerosis and cardiovscular disease[J].Circulation,2004,109(18):2175-2180.
[13]Goolledge J,McCann M,Mangan S,et al. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis[J].Stroke,2004,35(7) :1636-1643.
[14]Shin JY, Shin YG, Chung CH. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes[J]. Diabetes Care, 2006,29(4):1664-1666.
[15]Golledge J, Leicht AS, Crowther RG, et al. Determinants of Endothelial Function in a Cohort of Patients with Peripheral Artery Disease[J]. Cardiology,2008,111(1):51-56.
[16]Orita Y, Yamamoto H, Kohno N, et al. Role of osteoprotegerin in arterial calcification: development of new animal model[J]. Arterioscler Thromb Vasc Biol,2007,27(17):2058-2064.
[17]Morony S, Tintut Y, Zhang Z, et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice[J]. Circulation,2008,117(7):411-420.
[18]Jian B,Narula N,LiQ,et al.Progression of aortic valve stenosis:TGF-beta l is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis [J].Ann thorac Surg,2003,75(4):457-465.
[19]Nybo M, Rasmussen LM. Osteoprotegerin released from the vascular wall by heparin mainly derives from vascular smooth muscle cells[J]. Atherosc lerosis,2008, 201(1): 33-35.
[20]Candido R, Toffoli B, Corallini F,et a1.Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo[J]. J Vasc Res, 2010,47(3):252-261.
[21]Zhang J,Fu M,Myles D,et al.PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways[J].Febs Lett,2002,521(2):180-184.
[22]Zannettino AC,Holding CA,Diamond P,et a1.Osteoprotegerin (OPG)is localized to the Weibel-Palade bodies of human vascular endotbelial cells and is physically associated with von Willebrand factor[J].J Cell Physiol,2005,204 (2):714-723.
[23]Pritzker LB,Scatena M,Giachelli CM.The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival[J].Mol Biol Cel1,2004,15 (6):2834-2841.
[24]Malyankar U,Scatena M,Suchland K,et a1. Osteoprotegerin is an avb3-induced.NF-kB -dependent survival factor for endothelial cells[J].Biol Chem,2000,275(28):20959-20962.
[25]Soufi M ,Schoppet M ,Sattler AM ,et a1. Osteoprotegeringene polymorphisms in men with coronary artelT disease[J].J Clin Endocrinol Metab,2004,89(8):3764-3768.
[1]杨 琛,殷思雨,张春妮.糖化低密度脂蛋白与糖尿病患者动脉粥样硬化的相关研究[J].医学研究与战创伤救治(原医学研究生学报),2013,15(03):269.[doi:10.3969/j.issn.1672-271X.2013.03.020]
[2]罗助荣,林 毅,张克己,等.福建地区汉族人群骨保护素基因rs2073617T/C多态性与急性冠脉综合征病变程度的关系[J].医学研究与战创伤救治(原医学研究生学报),2011,13(05):385.
LUO Zhu-rong,LIN Yi,ZHANG Ke-ji,et al.Correlation between osteoprotegerin gene rs2073617T/C polymorphism and severity of acute coronary syndromes in Fujian area[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2011,13(06):385.
[3]李艳秋,穆红艳.超声检测脑梗死患者颈动脉粥样硬化的价值[J].医学研究与战创伤救治(原医学研究生学报),2010,12(03):196.
[4]吴 平,全亚萍,陈顺中.2型糖尿病患者脑梗死与同型半胱氨酸的相关性研究[J].医学研究与战创伤救治(原医学研究生学报),2013,15(06):559.[doi:10.3969/j.issn.1672-271X.2013.06.030]
[5]庄 微综述,刘挺松审校.晚期糖基化终末产物受体在心血管疾病中的研究概况[J].医学研究与战创伤救治(原医学研究生学报),2014,16(06):629.[doi:10.3969/j.issn.1672-271X.2014.06.021]
[6]周 磊,范茂丹,史承勇.高同型半胱氨酸血症对大鼠颈总动脉平滑肌细胞增殖及Caspase-12蛋白表达的影响[J].医学研究与战创伤救治(原医学研究生学报),2016,18(01):21.[doi:10.3969/j.issn.1672-271X.2016.01.006]
ZHOU Lei,FAN Mao-dan,SHI Cheng-yong..Effect ofhyperhomocystinemia on the proliferation of rats common carotid artery vascular smooth muscle cells and expression of Caspase-12[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2016,18(06):21.[doi:10.3969/j.issn.1672-271X.2016.01.006]
[7]曹媛,姥义.糖尿病患者心外膜脂肪厚度与动脉粥样硬化相关性分析[J].医学研究与战创伤救治(原医学研究生学报),2020,22(01):79.[doi:10.3969/j.issn.1672-271X.2020.01.018]